|
Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
Written by: Celmade Editorial Team | AI-Assisted Content Medically Reviewed by: Stella Williams, Medical Aesthetic Injector Published: May 16th, 2026 | Last Reviewed: May 16th, 2026 View Reviewer Full Profile: celmade.co/pages/team-stella-williams |
|
Editorial Note: This article was drafted with AI assistance and reviewed, fact-checked, and approved by Stella Williams, a qualified Medical Aesthetic Injector. All clinical claims are supported by cited references. |
The aesthetic exosome market is growing rapidly and unevenly. Alongside genuinely well-characterised, rigorously manufactured Korean products with transparent documentation, the market contains preparations making compelling regenerative claims while providing minimal evidence of their actual content, source, or regulatory classification. For practitioners, the ability to evaluate exosome products on scientific and regulatory grounds is essential.
Korean manufacturers have brought the same pharmaceutical manufacturing discipline to exosome products that established Korean PDRN and HA skin boosters as global clinical standards. The best Korean exosome products are characterised at a level most European alternatives cannot match — with defined source cell types, validated isolation methods, exosome concentration and size distribution data, and appropriate regulatory documentation.
For clinical exosome applications, see the Complete Exosomes Practitioners Guide, Exosomes for Skin Rejuvenation, and Exosomes for Post-Procedure Recovery. Browse Celmade's exosome range.
Why Product Quality Matters More in Exosomes Than Other Injectables
Exosome product quality is uniquely important because biological activity depends on variables that are invisible and unrecoverable once compromised:
• Source cell biology determines cargo: Two products both labelled 'MSC-derived exosomes' may have fundamentally different cargo profiles depending on MSC subtype, passage number, and culture conditions. Without source documentation, cargo cannot be verified.
• Concentration determines dose: Exosome particle concentration (vesicles/ml) determines biological dose. Without NTA-confirmed concentration, 'one vial' may mean radically different biological doses across batches.
• Structural integrity is fragile: Membrane integrity enabling cargo delivery is destroyed by incorrect storage, temperature excursions, freeze-thaw cycles, and vigorous mixing. A shaken product looks identical but is biologically inactive.
• Contamination risk: Cell culture-derived preparations can contain residual culture media components, debris, and protein aggregates. Products without validated purification cannot confirm the absence of these contaminants.
Source Cell Types: What the Label Means Clinically
|
Source Cell Type |
Primary Cargo Profile |
Regulatory Consideration |
Clinical Positioning |
|
Adipose-derived MSC (AD-MSC) |
VEGF, FGF-2, TGF-beta, EGF, PDGF, anti-inflammatory cytokines, proliferative miRNAs. Most extensively studied for aesthetics. |
Human-derived — potential ATMP classification. Most products use proprietary processing to support CE device classification. |
Broadest aesthetic applicability: skin rejuvenation, hair, post-procedure recovery. Most common Korean manufacturer source. |
|
Umbilical cord-derived MSC (UC-MSC) |
Rich growth factor cargo similar to AD-MSC. Young tissue source hypothesis not clinically confirmed. |
Human-derived — same ATMP considerations as AD-MSC. |
Used in some Korean formulations. The 'young tissue' claim is marketing rather than established clinical evidence. |
|
Platelet-derived exosomes |
PDGF, VEGF, EGF, TGF-beta — similar to PRP but vesicle-bound for improved stability. |
Autologous (patient blood) or manufactured donor product — different regulatory classifications. |
Bridge between PRP and exosome categories. Familiar to PRP practitioners. |
|
Plant-derived exosomes |
Plant growth factors — structurally different from human equivalents. Topical mechanism only. |
Classifiable as cosmetic active or topical device. Cannot claim human growth factor receptor mechanism. |
Topical applications only. Lower regulatory burden. Cannot be injected under a device classification. |
|
Conditioned media / secretome |
Full secretome — exosomes plus free growth factors and proteins not vesicle-bound. Often marketed as exosomes. |
Variable classification — technically broader than purified exosomes. |
Products should specify whether purified exosomes or conditioned media. Ask explicitly. |
|
The source cell question to ask any supplier: 'What is the exact source cell type — tissue origin, cell type (MSC, platelet, plant), and whether the product is purified exosomes or conditioned media?' If the supplier cannot answer precisely with documentation, the product's biological activity cannot be reliably assessed. |
Product Characterisation: What Should Be Documented
|
Parameter |
What It Confirms |
Method |
Clinical Relevance |
|
Particle concentration (particles/ml) |
Number of vesicles per ml — the primary dose metric. Typically 10 to the 9th to 10 to the 10th particles/ml. |
Nanoparticle Tracking Analysis (NTA) — e.g. NanoSight, ZetaView. |
Enables dose-to-dose consistency. Without this, one vial cannot be compared to any clinical reference dose. |
|
Particle size distribution (nm) |
Mean diameter and range — confirms particles are in the exosome size range (30-150nm) not larger microvesicles or debris. |
NTA or Dynamic Light Scattering (DLS). |
Confirms genuine exosome-scale preparation. Particles above 200nm suggest contamination. |
|
Exosomal markers (CD9, CD63, CD81) |
Presence of exosome-specific tetraspanin surface proteins — confirms vesicles are genuine exosomes. |
Western blot or flow cytometry. |
The biological gold standard for exosome identity. Products without this data cannot be confirmed as genuine exosomes. |
|
Growth factor cargo profile |
Which growth factors are present and at what concentration — VEGF, FGF, TGF-beta, EGF. |
ELISA, proteomics, multiplex assay. |
Determines whether cargo matches claimed biological activity. |
|
Sterility and endotoxin testing |
Absence of microbial contamination and bacterial endotoxin within injectable limits. |
Compendial sterility test, LAL endotoxin assay. |
Non-negotiable for any injectable product. Must be confirmed per batch. |
|
Residual protein content (BSA) |
Absence of bovine serum albumin and other cell culture media proteins. |
BCA protein assay, mass spectrometry. |
BSA contamination is a known quality issue — can trigger immune reactions. |
Regulatory Classification: The ATMP Question
Human MSC-derived exosomes intended to exert biological action in human tissue may be classifiable as Advanced Therapy Medicinal Products (ATMPs) under UK and EU regulations. No aesthetic exosome product currently holds ATMP marketing authorisation in the UK. Commercially available injectable products rely on one of three classification strategies:
• CE Class III medical device: Assessed under MDR 2017/745 with a notified body. Subject to ongoing MHRA scrutiny — products making specific cellular biological activity claims may not be sustainably classified as devices.
• Cosmetic classification (topical only): Plant-derived topical exosome products avoid ATMP and device classification. Restricts claims and route of administration to topical only.
• Conditioned media approach: Some manufacturers argue extensive processing supports a device rather than ATMP classification. Regulatory acceptability is product-specific and subject to ongoing review.
|
Regulatory due diligence checklist for injectable exosomes: 1. Confirm specific regulatory classification (CE device, cosmetic, ATMP, or unclassified). 2. Request CE Certificate of Conformity identifying the product, notified body, and device class. 3. Confirm intended injectable use is consistent with the regulatory classification scope. 4. Confirm medical indemnity insurance covers injectable exosome treatments. 5. Confirm batch characterisation data (NTA, tetraspanin markers, sterility/endotoxin) is available. |
The Product Documentation Checklist
|
Document |
What It Confirms |
If Unavailable |
|
CE Certificate of Conformity |
Product assessed as CE Class III device under MDR 2017/745. Must name the specific product and notified body. |
Do not use for injectable purposes. If unavailable, regulatory status for injection cannot be confirmed. |
|
Source cell documentation |
Specific cell type, tissue origin, and whether purified exosomes or conditioned media. |
Request from manufacturer. If supplier cannot state source cell type with documentation, cargo cannot be assessed. |
|
Batch characterisation certificate |
For this batch: NTA concentration, size distribution, CD9/CD63/CD81 status, sterility and endotoxin results. |
Non-negotiable. Request for every order. |
|
Protein and cargo profile data |
Growth factor content (VEGF, FGF, TGF-beta, EGF) and ideally miRNA profile. |
Request product-level data. If unavailable, the claimed mechanism cannot be verified. |
|
Storage and stability data |
Shelf life, storage conditions, reconstitution protocol and post-reconstitution use window. |
Must be available in the product SPC before clinical use. |
|
Supplier regulatory authorisation |
Authorised UK/EU distributor — not a grey-market importer. |
Request distribution authorisation. Grey-market importers have no regulatory accountability. |
Product Formats: Lyophilised vs Liquid
|
Format |
Description |
Advantages |
Considerations |
|
Lyophilised (freeze-dried) |
Freeze-dried powder supplied in sealed vial. Reconstituted with provided diluent before use. |
Long shelf life (12-24+ months). Often room-temperature stable. Consistent concentration per vial. Dominant Korean injectable aesthetic exosome format. |
Correct reconstitution essential — gentle swirl only, never shake. Use within manufacturer window post-reconstitution (typically 2-4 hours). Errors are unrecoverable. |
|
Liquid (ready-to-use) |
Exosome preparation in liquid form — refrigerated or frozen. |
No reconstitution step required. Ready immediately. |
Shorter shelf life. Cold chain dependent. Freeze-thaw cycles destroy membranes — confirm no freeze-thaw during transit. |
|
Reconstitution protocol for lyophilised products: 1. Allow vial to reach room temperature before opening. 2. Add specified diluent volume per manufacturer protocol. 3. Gently swirl 30-60 seconds. Never shake — shaking destroys membrane integrity. 4. Allow 2 minutes for complete dissolution. 5. Use within manufacturer-specified window (typically 2-4 hours). Discard any remainder. |
Matching Korean Exosome Products to Clinical Applications
|
Application |
Product Requirements |
Volume / Session |
Key Note |
|
Post-microneedling / post-laser (topical) |
Sterile formulation for topical use. Can be lower concentration than injectable products. |
1-1.5ml full face |
Apply immediately post-procedure. Sterile technique on post-procedure skin. |
|
Skin rejuvenation (injectable) |
MSC-derived, characterisation data available. Particle concentration 10 to the 9th particles/ml minimum. |
2-4ml full face |
Confirm CE Class III device classification before purchasing. |
|
Hair rejuvenation (scalp injectable) |
MSC-derived with VEGF-rich cargo. Higher particle concentration preferred for scalp. |
3-5ml per session |
Same regulatory requirements as facial injectable. |
|
Combination with PDRN (same session) |
Any MSC-derived injectable product. No interaction with PDRN. |
Standard volumes for each product independently |
PDRN first (A2AR priming), exosomes second. Separate syringes. |
7 Questions to Ask Your Supplier Before Every Purchase
1. What is the exact source cell type — tissue origin, cell type, and passage number?
2. Is this a purified exosome preparation or conditioned media?
3. What is the particle concentration in particles/ml, confirmed by NTA?
4. Can you provide the batch characterisation certificate for this order? (NTA data, tetraspanin markers, sterility, endotoxin.)
5. What is the regulatory classification for injectable use — CE Class III device, cosmetic, or ATMP?
6. What are the storage and reconstitution requirements? (Diluent, volume, use-by post-reconstitution.)
7. Has the product been tested for residual BSA from cell culture media?
|
Celmade's exosome documentation standard: Products in Celmade's exosome range are sourced from Korean manufacturers providing: source cell documentation, NTA characterisation (concentration, size distribution, tetraspanin markers), per-batch sterility and endotoxin results, regulatory classification documentation, and reconstitution guidance — all on request. If your current supplier cannot provide characterisation data and regulatory classification documentation, Celmade's standard resolves this gap. |
Storage and Handling in Clinical Practice
• Lyophilised products — mostly room temperature stable: Most Korean lyophilised exosome preparations are stable at 15-25 degrees C. Always confirm from the specific product SPC.
• Never shake: The single most critical handling rule. Shaking destroys membrane integrity. Label storage: Do Not Shake.
• Single-use reconstitution: Use within the manufacturer-specified window post-reconstitution. Do not store reconstituted product. Discard remainder.
• Batch number recording: Record vial batch number in every patient record. Required for traceability.
Key Takeaways
• Source cell type determines cargo — demand explicit documentation. MSC-derived provides the broadest aesthetic-relevant growth factor and miRNA cargo.
• Characterisation data is non-negotiable — NTA concentration, size distribution, CD9/CD63/CD81 tetraspanin markers, per-batch sterility and endotoxin.
• Regulatory classification must be confirmed before injectable use — CE Class III device. Request the CE Certificate of Conformity. Confirm indemnity insurance covers injectable exosome treatments.
• Never shake the reconstituted product — exosome membrane integrity is destroyed by vigorous mixing. Gentle swirl only.
• Ask 7 questions before every purchase — source cell, purified vs conditioned media, particle concentration, batch CoA, regulatory classification, storage requirements, BSA contamination testing.
• Celmade's exosome range meets all these criteria — browse the exosome collection or contact Celmade for specific product documentation.
Related guides: Complete Exosomes Guide, Exosomes for Skin Rejuvenation, Exosomes for Hair Rejuvenation, Exosomes for Post-Procedure Recovery. See also Korean PDRN Products Selection Guide.
Frequently Asked Questions
Are all products marketed as exosomes actually exosomes?
No. Many products marketed as exosomes are actually: conditioned media (full cell secretome including free-floating growth factors not vesicle-bound), microvesicle preparations (larger vesicles 100-1000nm, not true exosomes), or plant extract preparations. A genuine exosome preparation must have NTA data confirming 30-150nm size range, CD9/CD63/CD81 tetraspanin marker confirmation, and particle concentration data. Without these, 'exosome' is an unverified marketing term.
What does exosome concentration mean and why does it matter?
Exosome concentration — expressed as particles/ml, typically 10 to the 9th to 10 to the 10th particles/ml — is the primary dose metric. More vesicles mean more growth factor delivery and more miRNA cargo per treatment. Always request and compare products on the basis of NTA-confirmed particle concentration.
How do I verify an exosome product is safe to inject?
Safety verification requires four confirmations: per-batch sterility testing result; bacterial endotoxin within injectable limits; absence of BSA or serum protein contamination confirmed by protein analysis; and appropriate regulatory classification (CE Class III device or equivalent) for injectable use.
What is the shelf life of a Korean aesthetic exosome product?
For lyophilised products stored at manufacturer-specified temperature, shelf life is typically 12-24 months from manufacture date. Post-reconstitution shelf life is 2-4 hours at room temperature. Always confirm specific shelf life from the batch CoA and SPC.
Is there a risk of immune reaction from exosome treatment?
Allogeneic MSC-derived exosomes carry a theoretical immunogenicity risk but available evidence suggests low immunogenicity. To reduce risk: review patients for immune hyperreactivity, use products tested for residual BSA contamination, and observe patients for 30 minutes post-injection.
|
Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
Medically reviewed by Stella Williams, Medical Aesthetic Injector. Last reviewed: May 16th, 2026. View Full Profile: celmade.co/pages/team-stella-williams |
References
1. Thery C et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles. 2018;7(1):1535750 — https://pubmed.ncbi.nlm.nih.gov/30637094/
2. Shafiei M et al. Exosome-mediated delivery of proteins and growth factors for skin regeneration. Journal of Nanobiotechnology. 2020;18(1):134 — https://pubmed.ncbi.nlm.nih.gov/32993671/
3. Lim ZW et al. Exosomes as next-generation diagnostics and therapeutics in dermatology. Experimental Dermatology. 2022;31(2):179-196 — https://pubmed.ncbi.nlm.nih.gov/34448521/
4. UK MHRA guidance on Advanced Therapy Medicinal Products — https://www.gov.uk/guidance/advanced-therapy-medicinal-products
5. Harrell CR et al. Molecular mechanisms of mesenchymal stem cell-derived secretome. Cells. 2019;8(5):467 — https://pubmed.ncbi.nlm.nih.gov/31083463/
